Form 4 Filing for Niki BioSolutions, Inc.

Kira Sheinerman, a 10% owner, director, and insider of Niki BioSolutions, Inc., reported the acquisition of 8,000 stock options on July 22, 2026. These options, with an exercise price of $8.83, are for the company's Common Stock and have an expiration date of July 22, 2036. The options vest in installments, with 2,000 options vesting immediately upon the closing of a merger and the remaining 6,000 vesting quarterly over the subsequent period. Sheinerman holds a total of 8,000 shares post-transaction. This transaction is classified as an acquisition of securities.